Horizon Seeks Other Deals As Depomed Thwarts Takeover
This article was originally published in Scrip
Executive Summary
Horizon Pharma plc has abandoned its hostile pursuit of Depomed Inc. after a judge in California came down against the Ireland-based bidder both on its argument that a poison pill adopted by Depomed might be unlawful, and on Depomed's motion for an injunction against Horizon's offer for its alleged use of confidential information.
You may also be interested in...
Depomed CEO, Two Board Members Out In Settlement With Investor
Starboard has been trying to replace Depomed management and add its own members to the specialty pharma company's board since at least April 2016. This is the investor's second settlement with the pain and neurology specialist.
Raptor Buy Bolsters Horizon's Orphan Business As Primary Care Foots The Bill
Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”